GUMDROP : UMD - A Phase 2, Open-label, Multicenter Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer

Created by Nancy Dawson, last modified on Jun 25, 2013
Description:PSMA ADC 2301 is a Phase 2, open-label, study to assess the anti-tumor activity and tolerability of PSMA ADC in subjects with metastatic castration-resistant prostate cancer (mCRPC). Subjects must have received at least one taxane-containing chemotherapy regimen (e.g. docetaxel, cabazitaxel). If a subject has received more than two cytotoxic chemotherapy regimens, Sponsor approval is required for study participation. Subjects must also have received and progressed on abiraterone acetate and/or enzalutamide. If a subject is unable to receive abiraterone acetate and/or enzalutamide, Sponsor approval is required for participation in the study. Subjects will receive up to eight doses of PSMA ADC approximately once every three weeks.
Link:http://clinicaltrials.gov/ct2/show/NCT01695044
Site:University of Maryland
Principal Investigator:Arif Hussain, MD